Biologic and targeted therapeutics in vitiligo

Area of Science:

• Dermatology
• Immunology
• Pharmacology

Background:

• Vitiligo is a progressive autoimmune disorder causing depigmented patches and significant psychological distress.
• Recent advances have elucidated the molecular and genetic factors, intracellular environment, and immune interplay in vitiligo pathogenesis.
• Numerous cytokines and signaling pathways are now recognized as contributors to the disease.

Purpose of the Study:

• To review the efficacy of biologic and targeted therapeutics for vitiligo treatment.
• To provide an in-depth analysis of newer therapeutic options and their potential complications.

Main Methods:

• A comprehensive literature search was performed on PubMed, COCHRANE Central, EMBASE, and Google Scholar.
• Keywords included "biologics," "vitiligo," "treatment," "repigmentation," "JAK inhibitors," "TNF-α inhibitors," and "IL17/23 inhibitors."
• Relevant studies and review articles were analyzed to assess therapeutic efficacy and complications.

Main Results:

• Conventional vitiligo treatments include corticosteroids, calcineurin inhibitors, phototherapy, and surgery.
• Janus kinase (JAK) inhibitors demonstrate good efficacy but require more randomized controlled trial (RCT) evidence.
• Targeted therapeutics show potential but are supported by limited evidence, necessitating further RCTs.

Conclusions:

• JAK inhibitors exhibit promising results and good tolerability; adjuvant phototherapy may improve outcomes over monotherapy.
• Tumor necrosis factor-alpha (TNF-α) inhibitors are best considered for vitiligo associated with other indicated autoimmune diseases.
• Further in vitro studies and clinical research are needed to clarify pathogenesis and develop targeted therapies, potentially including melanocyte induction and differentiation for enhanced repigmentation.